



# American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301)231-5529 Telex: 598-855 ATCCNORTH • FAX: 301-770-2597

## BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

### INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3  
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

IDEC Pharmaceuticals Corporation  
Attention: Dr. Mitchell Reff  
11099 N. Torrey Pines Road, #160  
La Jolla, CA 92037

Deposited on Behalf of: IDEC Pharmaceuticals Corporation

Identification Reference by Depositor:

ATCC Designation

<u>Escherichia coli</u> strain XL1 Blue containing a plasmid, Anti-CD20 in Anex 2 (G1,K)	69118
<u>Escherichia coli</u> strain XL1 Blue containing a plasmid, Anti-CD20 in TCAE 8	69119
<u>Escherichia coli</u> strain XL1 Blue containing a plasmid, Anti-CD20 in TCAE 12 (ANEX 1)	69120

The deposits were accompanied by: ☐ a scientific description ☒ a proposed taxonomic description indicated above.

The deposits were received November 4, 1992 by this International Depository Authority and have been accepted.

#### AT YOUR REQUEST:

☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested November 9, 1992. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Bobbie A. Brandon Date: November 10, 1992  
Bobbie A. Brandon, Head, ATCC Patent Depository

cc: Richard P. Burgoon, Jr. ✓

EXHIBIT A



# American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301)731-4528 Telex: 576-453 ATCCNORTH • FAX: 301-770-2587

## BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

### INTERNATIONAL FORM

#### RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3 AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Dartmouth Medical School  
Attention: Randolph J. Noelle  
640 W. Borwell Building  
Dartmouth Medical School  
1 Medical Center Drive  
Lebanon, NH 03756

Deposited on Behalf of: Trustees of Dartmouth College

Identification Reference by Depositor:

ATCC Designation

Mouse hybridoma IgG1 anti-human CD40 Ligand (gp39), 24-31  
Mouse hybridoma IgG1 anti-human CD40 Ligand (gp39), 89-76

HB 11712  
HB 11713

The deposits were accompanied by: ☐ a scientific description ☐ a proposed taxonomic description  
indicated above.

The deposits were received September 2, 1994 by this International Depository Authority and have  
been accepted.

#### AT YOUR REQUEST:

☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's  
right to receive, or if a U.S. Patent is issued citing the strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your  
responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years after the date of deposit, and for a  
period of at least five years after the most recent request for a sample. The United States and many  
other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested September 8, 1994. On that date, the cultures  
were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Annette L. Bada, Director, Patent Depository

Date: September 9, 1994

cc: Amy E. Mandragouras



rev: June 11, 2003

HOME (index HOME page)

Return (main CD antibody index page)

## CD CLUSTERED ANTIBODIES

(anti-Human and others as indicated)

NOTE: Please inquire for bulk or custom formulations (without preservative or carrier).

Research Diagnostics Inc offers a wide line of antibodies. Since no one antibody works best for all applications (flow cytometry, neutralization, blotting, histochemistry, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below. All products are for in vitro research use only-not for use in or on humans or animals-not for use in diagnostics. Price/availability/specifications subject to change without notice.

### CD154 (CD40 Ligand) Antibodies

#### Mouse anti-human CD154 antibodies

-3 clones & polyclonals

CATALOG#	CLONE#	Workshop	Host	Form	Price
RDI-CD40L-2431	24-31	VI	mIgG1	purified	\$325.00
RDI-CD40L-2431FT	24-31	VI	mIgG1	FITC	\$375.00
RDI-CD40L-2431BT	24-31	VI	mIgG1	Biotin	\$375.00
RDI-CD40L-2431PE	24-31	VI	mIgG1	PE	\$500.00
RDI-CD154abm-TP	Trap-1	VI	mIgG1	purified	\$325.00
RDI-CBL543	B-B29	VI	mIgG2a	purified	\$350.00

-see also rabbit and goat anti-CD40L antibodies -see below.

-see also recombinant human CD40-Ligand Antigen in our cytokine section

#### DATA SHEET: mouse anti-human CD 40L (gp39) clone 24-31

Catalog#: RDI-CD40L-2431 \$325.00/vial

Also available conjugated to FITC: #RDI-CD40L-2431-FT \$375.00/100T

also available Biotin conjugated cat#RDI-CD40L-2431BT \$375.00/100ug

also available PE conjugated: cat#RDI-CD40L-2431PE \$500.00/100T

Package Size: 100ug in 100ul (1mg/ml) 50mM sodium phosphate pH 7.5, 500mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin Sulfate (preservative).

Species: mouse IgG1

Antigen: human sgp 39 fusion protein

Purity: >95% immunoglobulin by SDS-PAGE. Purified from low FBS containing tissue culture supernatant using Protein A. Product contains <1% bovine immunoglobulin.

LOT# see sheet with shipment

CLONE: 24-31

Activity: Reacts with human CD40L. This antibody immunoprecipitates a CD40L (gp39) molecule of 36 kd. The antibody will stain activated CD3+human PBL and will functionally block MLR, sgp30 induced B cell proliferation and T cell dependent B cell differentiation.

Application: -Indirect fluorescence (approx 0.8ug/500K cells) -Briefly, ficoll prepared human peripheral white blood cells were stimulated by incubating 6 hours at 5 million cells/ml in RPMI 10% FBS media including 3ug/ml phytohemagglutinin-P and 1ng/ml Phorbol 12- Myristate 13-acetate. 500K cells were then washed and incubated 45 minutes on ice with 80ul of product at 10ug/ml. Cells were washed 2X and incubated with 50ul of secondary antibody and then washed 3X. A net of 5% of population of the cells stained positive with a mean shift of 306 fluorescent units compared to the IgG1 negative control.

-Blocking experiments-MLR (mixed Lymphocyte Response) can be blocked using approx 10ug/ml when 300K human PBL's(responders) are cultured with 100K irradiated allogenic human PBL's (stimulators). Inhibition can be observed by day 5 when using a 3H thymidine pulse to monitor proliferation. B cell differentiation induced by activated T cells and Il-2 can be measured by Ig production of IgD+ naive B cells.

Monoclonal anti-CD40L significantly inhibits this Ig production at levels of 1-10ug/ml.

-titers must be determined for each application

Storage: Store at 4 Deg C. DO NOT FREEZE.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.

References: Dr. Randolph J. Noelle, Dartmouth Medical School

It is the responsibility of the user to comply with all local/state and Federal rules in the use of this



UNITED STATES ADOPTED NAMES COUNCIL

RUTA FREIMANIS, Pharm.D., R.Ph., Secretary  
(312) 464-4045

American Medical Association  
515 North State Street  
Chicago, Illinois 60610


Telefax: 312-464-4184  
Telex: 280248 AMA CGO

September 25, 1996

II-64

IDEC Pharmaceuticals Corporation  
11011 Torreyana Road  
San Diego, CA 92121

Attn: John F. Wood  
Regulatory Affairs Associate



Dear Mr. Wood:

It is my pleasure to inform you that the USAN Council adopted **rituximab** as the United States Adopted Name for Idec Pharmaceutical Corporation's antineoplastic monoclonal antibody IDEC-C2B8; IDEC-102.

Enclosed is a copy of the Statement of Adoption on **rituximab**. I plan to schedule publication of this information in the journal of Clinical Pharmacology and Therapeutics unless you request a delay within the next thirty days. Please use the enclosed statement to provide comments or additions. If this information is accurate, and may be published, please initial the statement and return it to me.

Sincerely yours,

A handwritten signature in cursive script that reads "Ruta Freimanis".

Ruta Freimanis, PharmD  
Secretary, USAN Council

RF/gat

Enclosure: N96;65

SPONSORS: American Medical Association /American Pharmaceutical Association /U.S. Pharmacopoeial Convention, Inc.